Donate

• KRF is the leading ketamine assisted psychotherapy organization in the world.
• We have developed as a free-standing research organization, developing the options for utilizing ketamine to benefit human beings.
• We are the preeminent training organization, having trained over 1,200 practitioners. We are producing eight or more major programs in 2025-2026. 
• Our Ketamine Training Center is originating new programs to access KAP with our annual Advanced Sharing and our Dharma-K exploration of the integration of spirit and spiritual practices with the meditative expansiveness of the ketamine experience. Dharma K will be having its fifth annual program in May of 2027. For 2027, KTC is developing a new format for its Fundamentals programs titled The Whole K.
• KRF is in the process of creating a unique and comprehensive APP that will provide virtually all relevant information about ketamine and KAP titled the “Keta APP.  1 ) It has 3 component parts that are addressed to the public looking for guidance in selecting a ketamine program. 2) For those people who are struggling with the potential or actuality of ketamine dependency. 3) As a full reference for practitioners, along with a CE credit opportunity. We are seeking to be the repository for addressing the full spectrum of needs for practitioners of Ketamine and KAP. 
• Our Ketamine Psychotherapy Associates (KPA) membership organization has grown to over 180 practitioners, with new members joining frequently.
• We remain the only organization with Access to Care available to KPA members, offering financial support to those who cannot afford treatment.
• We are publishing our work and generating public awareness through lectures and podcasts. A chapter on KAP is included in the new Wiley handbook of psychology-forthcoming. Our clinical review of KAP adolescent psychotherapy will be published in the next few months. Recognition of KRF continues to grow.
• In the spring of 2026 we published and circulated our second edition of the Ketamine Guidelines: also available as a Kindle book in English and Spanish. This has served as the standard in ketamine work in the field and has had massive dissemination. 
• We have taken the lead in treating adolescents and their families. 
• We are building an international presence in cooperation with Clinica Synaptica. Our third annual summit conference will be held this October in Barcelona. Other events are in the planning stages.

Overview: As a free-standing research institute, we can design and conduct unique and beneficial research given ketamine’s legal status—worldwide. Developing protocols to be funded and administered under KRF’s non-profit umbrella, KRF has advantages that are creative in alleviating human suffering and engendering healing. We welcome new initiatives under our umbrella and encourage relationships with collaborating researchers. 

Each project has its own cost center, and donors to KRF may earmark their contributions. When conducting primary clinical research, KRF submits our protocols for approval to the FDA for an IND and to wcgIRB. Once approved, we delineate our projects on clinicaltrials.gov. 

Our Program Initiatives

The Phantom Limb Pain Protocol—FDA and IRB-approved. We have begun subject accrual for what we believe to be of great benefit to those suffering from the physical and emotional aftermaths of trauma and amputations. Our goal is to establish the protocol for application worldwide. 

Ketamine has indications for potential benefit for a variety of pain disorders, including phantom limb pain. Based on a compelling anecdote (our story appearing in Lucid News), we are conducting a proof-of-concept study to assess ketamine’s potential benefit for this syndrome, which causes so much suffering. 

We are pleased to report that in October of 2025, we received FDA and IRB approval for our study. The study will be conducted at 4 sites, with the goal of assessing and treating 30 patients over a 6-month period and providing a 12-month follow-up. 

$218,000 is our budget

International Protocol for Ketamine Treatment of Acute Emotional Trauma and Distress. 

In awareness of ketamine’s potential for the treatment of acute agitation, suicidality, and PTSD, and in response to the many horrors being visited on humans, we have developed ketamine protocols for the treatment of emotional reactions to acute traumatization. We have sent out our protocol as widely as possible in an effort to provide a guide to ketamine’s use as a therapeutic applicable to acute trauma. KRF serves as an initiator and a resource for practitioners. 

This is a collaboration, and to that end, we are building an international body, which we are calling the ICG, to create the conditions for applying ketamine and other modalities for acute care. This is unprecedented and has a growing literature and experience to validate our methodology. Intensive feedback from those on the ground is essential. This is a cooperative project and will grow in its scope and needs. It is created in the spirit of service and beyond borders with the intention of caring, kindness, and sharing. 

We are directly supporting trauma work with ketamine in Ukraine. Our attempt to provide trauma training with ketamine in Israel/Palestine continues—with difficulties and some success in having practitioners administer the protocol. In disaster recovery, the protocol was used following the devastating flood in North Carolina.

$35,000 is our budget 

The KAP Clinical Review

As the creators and initiators of KAP, we published our study of 235 patients in 2019. It remains the cornerstone of KAP’s success story. In the intervening years, we have accumulated experience and data for over 1000 additional patients, digitized in Vanderbilt University’s REDCap program, making it highly accessible for us to publish a major new report to the field. This project entails completing the patient charts in compliance with HIPAA and, with our statistician, compiling the data and presenting it in a paper that, in great detail, reflects KAP practice.  In 2024 Wolfson and Vaid published a comprehensive review of ketamine assisted psychotherapy in the Journal of Frontiers of Psychiatry.

The “Keta APP” 

KRF is in the process of creating a unique and comprehensive APP that will provide virtually all relevant information about ketamine and KAP titled the “Keta APP. This is an advanced AI innovation project, interactive in nature, containing information from all of Wolfson’s work and carefully selected contributions from other practitioners, with attributions. Additionally, it contains our Ketamine Guidelines as a resource. 

The “Keta APP” will be available to all interested practitioners; licensed practitioners will have the opportunity to be listed in our referral section. Practitioners and the public who use the app will receive thorough responses based on the app’s extensive database. Information regarding specific patient issues will not be provided, as the app is not a medical provider. Access to the app for those struggling with ketamine dependency issues will be free, and modest charges to be determined will apply differentially to the other two sections. We anticipate that, over time, the “Keta App” will generate funds for KRF’s research.

$100,000 is our budget